Description:

E1305 Follow-Up Disease Evaluation Form (RECIST) NCT00588770 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19FAD740-2B45-48C6-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19FAD740-2B45-48C6-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 9/19/12
  2. 1/8/15
  3. 6/8/15
Uploaded on:

June 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

E1305 Follow-Up Disease Evaluation Form (RECIST) NCT00588770

INSTRUCTIONS: Complete this form and submit original to the ECOG Coordinating Center within one week of registration. Keep a copy for your files.

ECOG clinical trial administrative data
Data amendment
On Treatment
On Treatment Report Period (since start of treatment)
Off Treatment
Off Treatment Report Period (since registration)
Disease assessment
Were disease assessment results obtained this report period?
TARGET LESIONS
Site Code
Method of Evaluation
cm
Nontarget Lesions
Follow-Up Status of Lesion
Cytology Result (For Site Code 04 effusion/ascites ONLY)
New Lesions
Was the appearance of any new lesions documented
Overall Response Per Recist Criteria - Target, Nontarget And New Lesions
Best Overall Response to date
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's health status
Comments

Similar models